FIELD MAP / TUMOR TYPE

Prostate cancer

Prostate cancer — an emerging, typically low-TMB target for therapeutic cancer vaccines.

Topic2 items2026-05-29 – 2026-06-08

Tumor types

Glioblastoma25 Melanoma23 Pancreatic cancer19 Colorectal cancer18 Lung cancer (NSCLC)17 Breast cancer11 Liver cancer (HCC)8 Kidney cancer (RCC)7 Lynch syndrome7 Head & neck cancer5 Ovarian cancer2 Gastric cancer2 Prostate cancer2 Bladder cancer1

Clinical

YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

Changhai Hospital is conducting a Phase 1 study of YS247, a personalized neoantigen-pulsed dendritic cell vaccine for metastatic castration-resistant prostate cancer. The trial will enroll 9 to 18 men across three dose levels to determine safety and maximum tolerated dose, while monitoring PSA levels and immune stimulation as key efficacy markers.

clinicaltrials · brief 2026-06-08 · published 2026-05-13

Clinical

YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

Changhai Hospital is testing YS247, a personalized neoantigen-pulsed dendritic cell vaccine, for metastatic castration-resistant prostate cancer. The Phase I study aims to determine safety and the maximum tolerated dose across three dose levels, while monitoring PSA levels and immune stimulation.

clinicaltrials · brief 2026-05-29 · published 2026-05-13